about
Low dose cytarabine monotherapy for acute myeloid leukaemiaHypomethylating agents for adult patients with acute myeloid leukaemiaInterleukin-2 as maintenance therapy for children and adults with acute myeloid leukaemia in first complete remissionInterleukin-2 as maintenance therapy for children and adults with acute myeloid leukaemia in first complete remissionHypomethylating agents for adult patients with acute myeloid leukaemiaLow dose cytarabine monotherapy for acute myeloid leukaemiaHistone deacetylase inhibition in the treatment of acute myeloid leukemia: the effects of valproic acid on leukemic cells, and the clinical and experimental evidence for combining valproic acid with other antileukemic agentsReduced-intensity conditioning allogeneic hematopoietic-cell transplantation for older patients with acute myeloid leukemiaDefining and Treating Older Adults with Acute Myeloid Leukemia Who Are Ineligible for Intensive TherapiesVolasertib for AML: clinical use and patient considerationFavorable prognostic impact of NPM1 mutations in older patients with cytogenetically normal de novo acute myeloid leukemia and associated gene- and microRNA-expression signatures: a Cancer and Leukemia Group B study.Acute myeloid leukemia: 2012 update on diagnosis, risk stratification, and management.Therapy-related myeloid neoplasms: pathobiology and clinical characteristicsTargeting acute myeloid leukemia with TP53-independent vosaroxin.Sequential phase II Southwest Oncology Group studies (S0112 and S0301) of daunorubicin and cytarabine by continuous infusion, without and with ciclosporin, in older patients with previously untreated acute myeloid leukaemiaSpecific genomic regions are differentially affected by copy number alterations across distinct cancer types, in aggregated cytogenetic data.Outcome of older patients with acute myeloid leukemia: an analysis of SEER data over 3 decades.Azacitidine for Front-Line Therapy of Patients with AML: Reproducible Efficacy Established by Direct Comparison of International Phase 3 Trial Data with Registry Data from the Austrian Azacitidine Registry of the AGMT Study GroupVarious distinctive cytogenetic abnormalities in patients with acute myeloid leukaemia aged 60 years and older express adverse prognostic value: results from a prospective clinical trial.Clofarabine plus cytarabine compared with cytarabine alone in older patients with relapsed or refractory acute myelogenous leukemia: results from the CLASSIC I TrialTwo dosing regimens of tosedostat in elderly patients with relapsed or refractory acute myeloid leukaemia (OPAL): a randomised open-label phase 2 study.Decitabine: a review of its use in older patients with acute myeloid leukaemia.Pneumonia during remission induction chemotherapy in patients with acute leukemia.Phase I study of oral clofarabine consolidation in adults aged 60 and older with acute myeloid leukemia.Efficacy and tolerability of treatment with azacitidine for 5 days in elderly patients with acute myeloid leukemia.REVEAL-1, a phase 2 dose regimen optimization study of vosaroxin in older poor-risk patients with previously untreated acute myeloid leukaemia.Complex karyotype, older age, and reduced first-line dose intensity determine poor survival in core binding factor acute myeloid leukemia patients with long-term follow-up.Panobinostat as part of induction and maintenance for elderly patients with newly diagnosed acute myeloid leukemia: phase Ib/II panobidara studyDaily practice management of myelodysplastic syndromes in France: data from 907 patients in a one-week cross-sectional study by the Groupe Francophone des MyelodysplasiesCharacteristics predicting outcomes of allogeneic stem-cell transplantation in relapsed acute myelogenous leukemia.Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia.What are the endpoints of therapy for acute leukemias? Old definitions and new challenges.Effect of age on outcome of reduced-intensity hematopoietic cell transplantation for older patients with acute myeloid leukemia in first complete remission or with myelodysplastic syndrome.Randomized trial of two schedules of low-dose gemtuzumab ozogamicin as induction monotherapy for newly diagnosed acute myeloid leukaemia in older patients not considered candidates for intensive chemotherapy. A phase II study of the EORTC and GIMEMAReduced-intensity conditioning hematopoietic stem cell transplantation in patients over 60 years: hematologic malignancy outcomes are not impaired in advanced ageInteractions and relevance of blast percentage and treatment strategy among younger and older patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS)Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine.A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as front-line therapy for patients aged 60 years and older with acute myeloid leukemia and high-risk myelodysplastic syndromeAlternative donor transplantation for older patients with acute myeloid leukemia in first complete remission: a center for international blood and marrow transplant research-eurocord analysis.Clinical activity of sequential flavopiridol, cytosine arabinoside, and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemia.
P2860
Q24186270-E5AC2A96-8463-46BA-B831-E08C3F7894F3Q24186284-39BE8112-E907-410B-A42C-22564235BC3AQ24187927-41277AF9-18BD-4384-AB88-D8965CC92AE4Q24202630-F08D75B2-EF61-4E4E-9184-F751BB6AFA9DQ24234645-81DE7DDA-2E0E-47BF-814A-E688FD2A8D11Q24234680-9C2103A9-8AF8-48A2-BCB1-AC02D206FB5EQ24633763-68513FC8-0E14-4FFD-95C1-4438D6932919Q26744283-605C1FEB-A4DB-44AC-9B08-52460606F03DQ26772235-565AA7C9-2850-4AA9-93E7-AA1BC2F8345CQ26801131-0790AD06-0C33-4BDC-BD85-10245F1E4C8FQ27851545-AC4EEEFA-A51B-45BC-BEDE-C364ABC676B5Q27851694-67D0B5C1-4F9F-4EA1-AB72-244540E320ACQ28386366-1A367FAD-3598-4692-9F82-F489E388CF47Q30245472-7BDC819D-E8DB-4C8C-B3D9-090F8866FE19Q30497200-91CB2479-50E6-432D-98C7-E978C48CD9BDQ30560230-8408C71F-0FDC-40BA-BB46-24DEA3F80FD9Q30620658-9CBFA141-C0DD-4EF2-980F-D8D59ABCB01DQ31163049-ACC00A6F-3EAC-41C7-A40E-EC4EAC8F1E95Q33264716-4B41F8C1-C1E2-4189-84F7-8EE2B0C9AA04Q33401218-589BC6BB-D8AC-42A7-8D3D-375D441C99EBQ33406190-92991D09-80F5-4D05-8C82-AE1FC6ECBB58Q33407030-27589A5D-2DDE-483F-804F-97897FDBDFD2Q33410062-22088EF0-311E-4832-B526-446E4DE9B16CQ33412609-8EE6B420-7159-4916-AD06-3CB9A1ADCFF2Q33417145-48B33CBB-9AFF-402F-A288-38DF8289A1A6Q33418735-FAC55AF5-94BC-4DFE-9CD0-A4FAC6ED67C8Q33421005-F0E2D20A-9BA4-463F-A436-DA405B4D2DD9Q33424306-346AA1B3-845E-49FF-96C3-73EDF05BC355Q33518976-590D3701-DBD7-4D90-9F9E-1A04863A0F09Q33611146-D52701B8-96FB-4CEF-96E4-93ABF965CC07Q33702409-324A6B87-4ACC-42A0-BE9E-672F6F157108Q33775647-669CA2FA-F656-450D-8C18-1D889FA88568Q33813439-DDD488D1-07A8-405B-BFB6-57490A007AA9Q33828797-96989298-42B8-4A03-92BD-A18C4C0D1C1EQ33838116-6FD79470-A027-4670-BCF2-8BF5DE183455Q33840247-EF601799-C40F-4D8F-B50F-6FBCB10DB470Q33841988-C8DBE1D0-794A-41CF-B7E4-DAA04B87F291Q33843955-DD6339D2-7F1D-4887-AE49-D01B2B4797F2Q33859061-15C439B7-8ECC-410D-B3DC-9F7FB2FCE963Q33872754-8259D307-2DC1-4435-8337-07427C6FA5C5
P2860
description
2006 nî lūn-bûn
@nan
2006 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Age and acute myeloid leukemia.
@ast
Age and acute myeloid leukemia.
@en
Age and acute myeloid leukemia.
@nl
type
label
Age and acute myeloid leukemia.
@ast
Age and acute myeloid leukemia.
@en
Age and acute myeloid leukemia.
@nl
prefLabel
Age and acute myeloid leukemia.
@ast
Age and acute myeloid leukemia.
@en
Age and acute myeloid leukemia.
@nl
P2093
P2860
P1433
P1476
Age and acute myeloid leukemia.
@en
P2093
Cheryl L Willman
David R Head
Holly Gundacker
Jeanne E Anderson
John E Godwin
Marilyn L Slovak
P2860
P304
P356
10.1182/BLOOD-2005-09-3724
P407
P577
2006-02-02T00:00:00Z